Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 7/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.95 |
| ▸ | BLM | P54132 | 4/20 | 0.78 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL13293462 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL65495 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL19680109 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL12210779 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3124 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL14311544 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL19665229 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL15502093 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL19665230 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3125 | 1.00 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307334-A1 | USE OF SOBETIROME AND PRODRUGS AND DERIVATIVES THEREOF FOR TREATING PITT-HOPKINS SYNDROME | OREGON HEALTH & SCIENCE UNIVERSITY | 2024-09-19 | — | — | US | claimed |
| EP-4106722-A1 | PRESSURISED METERED DOSE INHALERS COMPRISING A BUFFERED PHARMACEUTICAL FORMULATION | Chiesi Farmaceutici S.p.A. (IT) | 2022-12-28 | — | — | EP | claimed |
| EP-0843676-B1 | PREPARATIONS CONTAINING IPRATROPIUM BROMIDE ENANTIOMER WITH A PROLONGED DURATION OF ACTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-11-07 | — | — | EP | claimed |
| US-20260102381-A1 | Muscarinic Agent Combinations | Syremis Therapeutics, Ltd. (IL) | 2026-04-16 | — | — | US | disclosed |
| US-12565710-B2 | Photodefined aperture plate and method for producing the same | STAMFORD DEVICES LIMITED (IE) | 2026-03-03 | — | — | US | disclosed |
| US-20250313651-A1 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES | SANOFI (FR) | 2025-10-09 | — | — | US | disclosed |
| US-20240344226-A1 | PHOTODEFINED APERTURE PLATE AND METHOD FOR PRODUCING THE SAME | STAMFORD DEVICES LIMITED (IE) | 2024-10-17 | — | — | US | disclosed |
| US-20240307334-A1 | USE OF SOBETIROME AND PRODRUGS AND DERIVATIVES THEREOF FOR TREATING PITT-HOPKINS SYNDROME | OREGON HEALTH & SCIENCE UNIVERSITY | 2024-09-19 | — | — | US | disclosed |
| US-20240287170-A1 | METHODS FOR TREATING SYSTEMIC SCLEROSIS | SANOFI (FR) | 2024-08-29 | — | — | US | disclosed |
| CN-117940115-A | Compositions, methods, and systems for aerosol drug delivery | 阿斯利康制药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117915892-A | Compositions, methods, and systems for aerosol drug delivery | 阿斯利康制药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11389601-B2 | Photodefined aperture plate and method for producing the same | STAMFORD DEVICES LIMITED (IE) | 2022-07-19 | — | — | US | disclosed |
| EP-3505173-B1 | PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220184031-A1 | DUAL ANTAGONIST OF PGD2/DPR2 AND THROMBOXANE A2/TPR RECEPTORS AND USE FOR TREATMENT OF MALADAPTIVE IMMUNE RESPONSE OR THROMBOTIC DIATHESIS | APPLIED MEDICAL TECHNOLOGIES LLC (US) | 2022-06-16 | — | — | US | disclosed |
| EP-1809243-B2 | AEROSOL SUSPENSION FORMULATIONS CONTAINING TG 227 EA AS A PROPELLANT | BOEHRINGER INGELHEIM INT (DE) | 2022-06-08 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3976181-A1 | METHODS FOR TREATING SYSTEMIC SCLEROSIS | SANOFI (FR) | 2022-04-06 | — | — | EP | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| EP-0843676-A1 | IPRATROPIUM BROMIDE ENANTIOMER WITH A PROLONGED DURATION OF ACTION | BOEHRINGER INGELHEIM KG (DE) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997005136-A1 | IPRATROPIUM BROMIDE ENANTIOMER WITH A PROLONGED DURATION OF ACTION | BOEHRINGER INGELHEIM KG (DE) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565710-B2 | Photodefined aperture plate and method for producing the same | PSMD9, UBAP2L, PSENEN | CHRM3 2507/4885CHRM2 980/4885CHRM5 1476/4885 |
| US-20260102381-A1 | Muscarinic Agent Combinations | CHRM1, CHRM4, CHRM2 | CHRM3 4/4885CHRM2 3/4885CHRM5 5/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CHRM3 73/4885CHRM2 315/4885CHRM5 534/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CHRM3 156/4885CHRM2 531/4885CHRM5 751/4885 |
| US-20240307334-A1 | USE OF SOBETIROME AND PRODRUGS AND DERIVATIVES THEREOF FOR TREATING PITT-HOPKINS SYNDROME | SLC6A2, SPATS2L, SLC18A2 | CHRM3 3275/4885CHRM2 1373/4885CHRM5 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.